Atenolol: A promising alternative to propranolol for the treatment of hemangiomas

doi:10.1016/j.jaad.2010.11.056

Journal of the American Academy of Dermatology

Volume 65, Issue 2, August 2011, Pages 420-421

https://doi.org/10.1016/j.jaad.2010.11.056 Get rights and content

References (7)

M. De Graaf et al.
Adverse effects of propranolol when used in the treatment of hemangiomas: A case series of 28 infants
J Am Acad Dermatol
(2011)
C. Léauté-Labrèze et al.
Propranolol for severe hemangiomas of infancy
N Engl J Med
(2008)
C.H. Storch et al.
Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action
Br J Dermatol
(2010)

There are more references available in the full text version of this article.

Cited by (60)

Oral Atenolol for Infantile Hemangioma: Case Series of 46 Infants
2020, Actas Dermo-Sifiliograficas
El propranolol, un betabloqueante no selectivo, sigue siendo la primera línea de tratamiento para el hemangioma infantil problemático. Sin embargo, aunque poco frecuente, un subgrupo de pacientes experimenta efectos secundarios indeseables, lo que despierta el interés sobre otros betabloqueantes selectivos. Presentamos una amplia serie de casos de 46 lactantes tratados con éxito con atenolol, un bloqueante selectivo beta-1.
Propranolol, a non-selective beta-blocker, remains the first line of treatment for problematic infantile hemangioma. However, although rarely, a subset of patients experience undesirable side effects, raising interest in other selective beta-blockers. We present a large case series of 46 infants treated successfully with oral atenolol, a selective beta-1 blocker.
Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma
2023, European Journal of Pediatrics
Application of topical betaxolol to cure superficial infantile hemangioma: A pilot study
2022, Pediatrics International
Oral atenolol versus propranolol in the treatment of infantile hemangioma: A systematic review and meta-analysis
2022, Journal of Indian Association of Pediatric Surgeons
Meta-analysis of the efficacy and safety of oral atenolol versus oral propranolol in the treatment of infantile hemangioma
2022, Chinese Journal of Plastic Surgery
Aesthetic Outcome of Propranolol vs Atenolol Treatment of Children with Infantile Haemangioma
2022, Acta Dermato-Venereologica

View all citing articles on Scopus

: All authors participate in the Centre for Congenital Vascular Anomalies Utrecht.

: Funding sources: None.

: Conflicts of interest: None declared.

View full text

LetterAtenolol: A promising alternative to propranolol for the treatment of hemangiomas

J Am Acad Dermatol

Propranolol for severe hemangiomas of infancy

N Engl J Med

Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action

Br J Dermatol

Letter
Atenolol: A promising alternative to propranolol for the treatment of hemangiomas